Reported 3 days ago
Aristotle Atlantic’s Core Equity Strategy has divested its shares in Zoetis (NYSE:ZTS) due to rising competition in the animal health market, particularly in dermatology and parasiticides. The decision follows a decline in Zoetis's stock value, while Aristotle's strategy has outperformed the S&P 500 Index in Q2 2025. The firm seeks better investment opportunities in other healthcare sectors, given the premium valuation of Zoetis and ongoing competitive pressures.
Source: YAHOO